Part 1. Uric acid and losartan

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Pharmacology

Background:

• Hyperuricemia is a significant risk factor for hypertension and cardiovascular disease.
• Renal processes are central to the development, persistence, and correction of hyperuricemia.
• Medications can modulate serum uric acid levels by altering renal urate handling.

Discussion:

• Losartan, an angiotensin-receptor blocker, uniquely reduces serum uric acid by enhancing renal excretion.
• This uricosuric effect is attributed to losartan itself, not its metabolite E-3174.
• The mechanism involves a transient, dose-dependent, probenecid-like action on renal urate transport.

Key Insights:

• Losartan administration leads to increased urinary uric acid excretion (uricosuria).
• This uricosuria is not associated with adverse renal consequences, potentially due to increased urinary pH.
• The serum uric acid-lowering effect of losartan has been observed in patients with end-stage renal disease.

Outlook:

• While losartan demonstrates a distinct effect on serum uric acid compared to other angiotensin-receptor blockers, its clinical significance requires further validation.
• The hypothesis that reducing serum uric acid impacts cardiovascular disease progression needs formal testing.
• Further research is warranted to explore the long-term clinical benefits of losartan-induced uricosuria.